Europe Epilepsy Drugs Market to 2030 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Epilepsy Drugs Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Epilepsy Drugs Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Rising Incidence of Epilepsy Cases Accelerate Demand for Antiepileptic Drugs to Favor Market

5.2 Market Opportunities

5.2.1 Rising Clinical Trials for Epilepsy Drugs Provide Lucrative Market Opportunity

5.3 Future Trends

5.3.1 Rising Research & Development (R&D) activities are likely to remain key trends in the market

5.4 Impact of Drivers and Restraints

6. Europe Epilepsy Drugs Market Regional Analysis

6.1 Europe Epilepsy Drugs Market Overview

6.2 Europe Epilepsy Drugs Market Revenue 2020-2030 (US$ Million)

6.3 Europe Epilepsy Drugs Market Forecast Analysis

7. Europe Epilepsy Drugs Market Analysis – by Treatment

7.1 First Generation Anti-Epileptics

7.1.1 Overview
7.1.2 First Generation Anti-Epileptics: Europe Epilepsy Drugs Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Second Generation Anti-Epileptics

7.2.1 Overview
7.2.2 Second Generation Anti-Epileptics: Europe Epilepsy Drugs Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Third Generation Anti-Epileptics

7.3.1 Overview
7.3.2 Third Generation Anti-Epileptics: Europe Epilepsy Drugs Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Epilepsy Drugs Market Analysis – by Distribution Channel

8.1 Hospital Pharmacy

8.1.1 Overview
8.1.2 Hospital Pharmacy: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)

8.2 Retail Pharmacy Stores

8.2.1 Overview
8.2.2 Retail Pharmacy Stores: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)

9. Europe Epilepsy Drugs Market – Europe Analysis

9.1 Europe

9.1.1 Europe Epilepsy Drugs Market Breakdown, by Key Country, 2023 and 2030 (%)
9.1.1.1 Europe Epilepsy Drugs Market – Revenue and Forecast Analysis – by Country
9.1.1.1 UK: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)

9.1.1.1.1 UK: Europe Epilepsy Drugs Market Breakdown, by Treatment
9.1.1.1.2 UK: Europe Epilepsy Drugs Market Breakdown, by Distribution Channel

9.1.1.2 Germany: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)

9.1.1.2.1 Germany: Europe Epilepsy Drugs Market Breakdown, by Treatment
9.1.1.2.2 Germany: Europe Epilepsy Drugs Market Breakdown, by Distribution Channel

9.1.1.3 France: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)

9.1.1.3.1 France: Europe Epilepsy Drugs Market Breakdown, by Treatment
9.1.1.3.2 France: Europe Epilepsy Drugs Market Breakdown, by Distribution Channel

9.1.1.4 Russia: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)

9.1.1.4.1 Russia: Europe Epilepsy Drugs Market Breakdown, by Treatment
9.1.1.4.2 Russia: Europe Epilepsy Drugs Market Breakdown, by Distribution Channel

9.1.1.5 Italy: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)

9.1.1.5.1 Italy: Europe Epilepsy Drugs Market Breakdown, by Treatment
9.1.1.5.2 Italy: Europe Epilepsy Drugs Market Breakdown, by Distribution Channel

9.1.1.6 Rest of Europe: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)

9.1.1.6.1 Rest of Europe: Europe Epilepsy Drugs Market Breakdown, by Treatment
9.1.1.6.2 Rest of Europe: Europe Epilepsy Drugs Market Breakdown, by Distribution Channel

10. Competitive Landscape

10.1 Heat Map Analysis

10.2 Company Positioning and Concentration

11. Europe Epilepsy Drugs Market Industry Landscape

11.1 Overview

11.2 Mergers and Acquisitions

11.3 Agreements, Collaborations, and Joint Ventures

11.4 New Product Launches

11.5 Expansions and Other Strategic Developments

12. Company Profiles

12.1 Abbott Laboratories

12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments

12.2 Alkem Laboratories Ltd

12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments

12.3 GSK Plc

12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments

12.4 Novartis AG

12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments

12.5 Pfizer Inc

12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments

12.6 Sanofi SA

12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments

12.7 Teva Pharmaceutical Industries Ltd

12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments

12.8 UCB SA

12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments

13. Appendix

13.1 About Business Market Insights